MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Hu, Shimin; Y. Xu‐Monette, Zijun; Tzankov, Alexandar; Green, Tina; Wu, Lin; Balasubramanyam, Aarthi; Liu, Wei-min; Visco, Carlo; Li, Yong; N. Miranda, Roberto; Montes‐Moreno, Santiago; Dybkær, Karen; Chiu, April; Orazi, Attilio; Zu, Youli; Bhagat, Govind; L. Richards, Kristy; D. Hsi, Eric; W.L. Choi, William; Zhao, Xiaoying; Han van Krieken, J.; Huang, Qin; Huh, Jooryung; Z. Ai, Weiyun; Ponzoni, Maurilio; J.M. Ferreri, Andrés; Zhou, Fan; W. Slack, Graham; D. Gascoyne, Randy; Tu, Meifeng; Variakojis, Daina; Chen, Weina; S. Go, Ronald; Á. Piris, Miguel; Møller, Michael; Jeffrey Medeiros, L.; H. Young, Ken

doi:10.1182/blood-2012-10-460063

Public

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Published in Blood • Mar 1, 2013

Authors:

Shimin Hu

Zijun Y. Xu‐Monette

Alexandar Tzankov

Abstract

Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)-like and unfavorable activated B-cell (ABC)-like subtypes based on gene expression signatures. In this study, we analyzed 893 de novo DLBCL patients treated with R-CHOP (rituximab, cyclopho...

Subject

Diffuse large B-cell lymphoma

Lymphoma

Biology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!